Amryt’s Myalepta scores NICE backing for rare lipid disorder
Lipodystrophy is characterised by an abnormal distribution of fat in the body
Read More
Tag: Amryt
Green light for Amryt’s epidermolysis bullosa study
An Independent Data Monitoring Committee (IDCM) has recommended that Amryt’s pivotal Phase III EASE trial for AP101 – a potential treatment for Epidermolysis Bullosa (EB) – should continue, raising hopes for a new therapy for the condition.
Read More
Amryt in-licenses novel gene therapy platform from UCD
UK biotech Amryt has secured itself access to a novel gene therapy platform that could give rise to a new treatment option for patients with Epidermolysis bullosa (EB), a group of rare inherited skin disorders that cause the skin to become very fragile.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
